George Benjamin J, Eichinger Jessica B, Richard Thomas J
Department of Hematology/Oncology, Brooke Army Medical Center, Ft Sam Houston, TX, USA.
South Med J. 2009 Sep;102(9):974-6. doi: 10.1097/SMJ.0b013e3181b1d2fa.
A 65-year-old female patient with glioblastoma multiforme (GBM) developed aplastic anemia following treatment with temozolomide. Following her diagnosis of GBM, the patient received standard treatment with surgery, concomitant radiation therapy and temozolomide followed by adjuvant temozolomide. On day 14 of her adjuvant treatment, she developed profound fatigue and spontaneous bruising and was noted to be severely pancytopenic. After an extensive workup, she was found to have aplastic anemia on bone marrow bipsy. Further studies did not reveal any other etiology and she was not on any other medications known to cause aplastic anemia. There have been two previously published cases involving aplastic anemia due to temozolomide. This case represents a rare but potentially fatal toxicity from temozolomide.
一名65岁的多形性胶质母细胞瘤(GBM)女性患者在接受替莫唑胺治疗后发生了再生障碍性贫血。在被诊断为GBM后,该患者接受了标准治疗,包括手术、同步放疗和替莫唑胺,随后进行辅助性替莫唑胺治疗。在辅助治疗的第14天,她出现了极度疲劳和自发性瘀伤,并且被发现严重全血细胞减少。经过广泛的检查,她在骨髓活检中被发现患有再生障碍性贫血。进一步的研究未发现任何其他病因,并且她没有服用任何其他已知会导致再生障碍性贫血的药物。之前已经有两例关于替莫唑胺导致再生障碍性贫血的病例报道。该病例代表了替莫唑胺一种罕见但可能致命的毒性。